Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ: GOSS )

1.310 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Gossamer Bio Announces $120 Million Private Placement Financing
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
From Gossamer Bio, Inc.
Via Business Wire
Where Gossamer Bio Stands With Analysts
Analysts have provided the following ratings for Gossamer Bio (NASDAQ:GOSS) within the last quarter: 
Via Benzinga
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
71 Biggest Movers From Yesterday
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga
Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program
Via Benzinga
Recap: Gossamer Bio Q4 Earnings
Gossamer Bio (NASDAQ:GOSS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
Upgrades 
Via Benzinga
Gossamer Bio Earnings Preview
Gossamer Bio (NASDAQ:GOSS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 32.4% to $7.43 during Wednesday's regular session. Sunshine Biopharma's stock is trading at a volume of 46.8... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Keros Therapeutics (NASDAQ:KROS) stock moved upwards by 26.51% to $41.75 during Monday's regular session. Keros Therapeutics's stock is trading at a volume... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 50% to close at $3.60 on Monday after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from... 
Via Benzinga
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers ADMA Biologics (NASDAQ:ADMA) stock rose 18.79% to $1.77 during Monday's pre-market session. The company's market cap stands at $226.8 million. The company... 
Via Benzinga
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.